Key Insights

Highlights

Treatment Research

1 treatments under study, led by Anticd20 Rituximab

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00202930Phase 2Terminated

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Showing all 1 trials

Research Network

Common Treatments

  • Anticd20 Rituximab1

Active Sponsors

  • Genentech, Inc.1
  • Jean M. Tersak, M.D.1

Related Conditions

  • Neuroblastoma1

Activity Timeline